The management of patients with transthyretin amyloidosis includes 2 main categories of disease-modifying therapies. This video discusses the role of TTR stabilizers and TTR silencers/knockdown agents along with heart failure and arrhythmia management for the management of patients with cardiac ATTR.
Please visit our post-module evaluation survey as well!
Link to survey: www.surveymonk...
Visit our website: hfsa.org/cardi...
HFSA LinkedIn: / hfsa
HFSA Twitter: / hfsa
HFSA Learning Center: learningcenter...
15 окт 2024